Weight Loss Medication UK Statistics 2026: 60+ Data Points on Adoption, Demographics, and the NHS vs Private Market

Published on: April 26, 2026

Medically reviewed by

Ashis Tandukar

Superintendent Pharmacist · Reg: GPhC No. 2084170

Around 1.6 million UK adults used a weight loss drug like Mounjaro or Wegovy in the year leading up to early 2025, according to a UCL study published in BMC Medicine. By July 2025, IQVIA estimated more than 2 million people were paying privately for these medications — almost seven times the number receiving them through the NHS. Another 3.3 million Britons say they want to start within the next year.

This is the largest, fastest-shifting category in UK medicine right now, and the data on it is fragmented across NHS England, NICE, IQVIA, the Smoking Toolkit Study, the Health Survey for England, the MHRA and a handful of peer-reviewed UK cohort studies. We pulled the most recent figures from each, traced everything back to its primary source, and dropped anything we couldn't verify.

What follows is a 2026 snapshot of how many people are actually using weight loss injections in the UK, who they are, what they're taking, and how the NHS rollout compares with the private market most patients are still relying on.

1. How many people in the UK actually use weight loss injections?

The headline number depends on whose definition you use. The UCL Smoking Toolkit Study — a nationally representative survey of 5,260 adults across England, Wales and Scotland — estimated 1.6 million adults used a GLP-1 medication for weight management between early 2024 and early 2025. IQVIA's prescription supply data, which counts dispensed packs rather than survey self-reports, put the figure at around 1.5 million in March 2025 alone, and over 2 million paying out-of-pocket by July 2025. Different methodologies, same direction of travel: the population using these drugs has roughly doubled in 12 months and shows no sign of slowing.

The IQVIA figure is the more conservative one because it only counts medicines actually dispensed through pharmacies and hospitals; it excludes illegally imported product. The UCL figure includes anyone who self-reports having used a relevant drug, which captures grey-market and intermittent use the prescription data misses. Both confirm the same headline: the UK is now the largest anti-obesity medication market in Europe.

2. Mounjaro vs Wegovy: which drug UK patients are actually taking

The 2026 UK weight loss landscape is, in practice, a Mounjaro market. The UCL study found that four out of every five people taking a GLP-1 medication exclusively for weight loss were on tirzepatide (sold as Mounjaro), with semaglutide products (Wegovy, Ozempic, Rybelsus) and liraglutide (Saxenda) splitting the rest. Mounjaro's dominance reflects both its superior weight loss in head-to-head trials and the speed at which UK private providers brought it to market after MHRA licensure in November 2023. NICE accepted in late 2024 that tirzepatide was likely more effective than semaglutide alongside diet and exercise.

The trial data overstates what most people see in practice — clinical trial participants get structured dietary support, free medication, and weekly check-ins. Real-world weight loss in the UK has been less consistent. A retrospective Clinical Practice Research Datalink study of 589 GLP-1 RA patients found only 33.4% lost ≥5% of their baseline weight at 12 months, well below the trial figure. The gap is mostly explained by adherence and dose titration, not by the drugs being weaker than advertised.

3. NHS vs private: the two parallel realities

The UK is running two largely separate weight loss medication systems in 2026: a small, slow, criteria-heavy NHS pathway, and a much larger private market that most people are quietly using instead. NICE's final guidance (TA1026) on tirzepatide for obesity, published 23 December 2024, recommended the drug for adults with a BMI of 35 or more (lower for some minority ethnic backgrounds) plus at least one weight-related comorbidity — about 3.4 million eligible people in England. NHS England then negotiated a 12-year phased rollout with NICE, with a target of 220,000 patients in the first three years.

The reality on the ground has fallen well short. A BMJ Freedom of Information investigation published September 2025 found that just 18 out of 42 ICBs (43%) had started prescribing in line with the rollout plan two months after launch, and that NHS England year-one funding covered only around 14,417 patients across reporting ICBs — roughly 10% of the 220,000 three-year target. From 1 April 2026, prescribing for obesity is being moved into the GP contract via Quality and Outcomes Framework indicators, but participation is voluntary and several ICBs have already said they will tighten criteria further.

For most people who are clinically overweight or obese but don't tick all five Phase 1 boxes, the NHS pathway is effectively closed for now. That is why the private market has absorbed most of the demand — and why patients who would qualify on a less restrictive system are routinely surprised when their GP cannot help. Our NHS eligibility guide walks through the Phase 1 criteria in plain English.

4. The price of going private: what UK patients are actually spending

Private weight loss medication has become a genuinely large category of out-of-pocket health spending in the UK. IQVIA data presented at Sigma 2025 showed that private medicine spending overall grew from £503 million to £784 million in the year to October 2025 — a 56% jump — with around £210 million of that directly attributable to weight management drugs. That makes private weight loss medication one of the fastest-growing single line items in UK consumer health.

The picture got more complicated in mid-2025. On 14 August, Eli Lilly announced that the UK list price of Mounjaro for private patients would rise from 1 September 2025. The highest 15 mg dose moved from £122 per month to £330 — a 170% increase — with mid-range doses rising 30–138%. Lilly framed this as an alignment with European list prices; in practice, the move came shortly after pressure from the Trump administration to raise drug prices outside the US. NHS pricing was unaffected under a separate agreement.

The cost picture for individual patients is more nuanced than the list-price headlines suggest. Lilly opened a rebate scheme to UK pharmacies that completed a commercial agreement, and several large online pharmacies froze their patient prices into late 2025 by absorbing the difference. Even so, monthly costs at higher doses moved meaningfully upward through 2025. For a current side-by-side of UK Wegovy pricing, our Wegovy cost in the UK guide is updated regularly.

5. Who is actually using these drugs in the UK

The user base is not the cliché of celebrities and biohackers. The UCL / BMC Medicine analysis paints a picture of middle-aged women managing real weight-related health concerns, often alongside psychological distress. Use is twice as common among women as men (4.0% vs 1.7% of adults), peaks in the 45–55 age group (4.2%), and is meaningfully more common in adults reporting moderate or severe psychological distress in the past month (3.7% vs 2.4%). Use was similar across socioeconomic grades — but interest in starting was significantly higher in more disadvantaged groups, where obesity prevalence is highest, signalling unmet demand the private system is not reaching.

That last number — more than a quarter of adults in England now living with obesity, two-thirds carrying excess weight — is the demand-side reality the rest of the data flows from. It is also why the gap between the 220,000-patient NHS plan and the millions of clinically eligible adults has translated so quickly into a multi-billion-pound private market. For the people in that population thinking about treatment, our overview of weight loss medication in the UK compares the realistic options.

6. Adherence, regain and the rebound problem

These are not "take a course and you're done" medications. Real-world adherence data from the UK and elsewhere makes that uncomfortably clear. A January 2026 Oxford-led systematic review across 37 studies and 9,341 adults found that around half of people stop GLP-1 treatment within 12 months. After stopping, weight returned at roughly 0.4 kg per month overall and 0.8 kg per month for the newer drugs (semaglutide and tirzepatide), putting most people back at baseline within 1.5 to 2 years.

Note on recency: the CPRD adherence figures above are the most rigorous UK-specific real-world dataset available, but cover initiation between 2009 and 2017 — predating Mounjaro entirely. They likely understate today's adherence because newer drugs have better tolerability and titration regimens. Newer global persistence studies show 1-year persistence has roughly doubled since 2021.

The single highest-impact data point in this section is the median 183 days. The realistic UK private patient stays on a GLP-1 programme for about six months. NICE guidance — and the trial data behind it — assumes longer. Closing the gap between what trials demonstrate and what UK patients actually get out of treatment is mostly about side-effect management, dose titration, cost stability, and protecting muscle during fast weight loss. We have covered the muscle-loss piece specifically in our guide on preserving strength while on GLP-1 medications.

7. The counterfeit and black market problem

The gap between demand and regulated supply has produced a substantial illegal market. UK Border Force seized 18,316 unregulated or illegal weight loss and diabetes products between February 2024 and May 2025. Across 2025 as a whole, the MHRA seized close to 20 million doses of illegally traded medicines worth around £45 million and removed more than 1,200 social media posts promoting them. In late October 2025, MHRA officers raided the UK's first known illicit weight loss injection production facility — a Northampton warehouse holding tens of thousands of empty pens, raw chemical ingredients and over 2,000 fake tirzepatide and unlicensed retatrutide pens. The agency described it as the largest single seizure of trafficked weight loss medicines on record globally.

The most dangerous contaminant identified in UK-seized counterfeit GLP-1 products is insulin, which can cause life-threatening hypoglycaemia in someone who is not diabetic. ITV's November 2025 testing of pens marketed as branded tirzepatide on social media found semaglutide instead, at concentrations up to 20 times the recommended starting dose. So-called GLP-1 "patches" — herbal supplements borrowing the GLP-1 name with no active drug whatsoever — are a separate and growing category we have covered in detail in our GLP-1 patches review.

UK weight loss medication by the numbers — summary

Methodology and sources

We aggregated data from primary sources only — original studies, regulatory bodies, government datasets and company press releases — and dropped any stat we could not trace back to a Tier 1 publication.

Where two market intelligence sources reported figures for the same metric (private market spend and patient counts in particular), we cite both and flag the methodological difference. Survey self-report (UCL / BMC Medicine) tends to capture more total users than dispensed-pack data (IQVIA), because it includes intermittent and grey-market users not visible in pharmacy supply chains.

Primary sources used in this article:

• University College London / BMC Medicine — Prevalence of use and interest in using glucagon-like peptide-1 receptor agonists for weight loss (Smoking Toolkit Study, n=5,260), January 2026
• IQVIA — Out-of-Pocket Obesity Market white paper (September 2025); IQVIA UK market data presented at Sigma 2025
• NICE — Technology Appraisal TA1026, Tirzepatide for managing overweight and obesity, 23 December 2024
• NHS England — Interim Commissioning Guidance: Implementation of NICE TA1026 and the NICE Funding Variation, March 2025
• BMJ — Freedom of Information investigation into ICB prescribing of tirzepatide (Mahase, September 2025)
• New England Journal of Medicine — SURMOUNT-1 (Jastreboff et al., 2022); SURMOUNT-5 (2025); STEP 1 (Wilding et al., 2021)
• BMJ Open Diabetes Research & Care — Real-world weight change, adherence and discontinuation among UK CPRD GLP-1 RA patients, 2022
• J Community Med Public Health — Talay & Vickers, Patient Adherence to a Digital Real-World GLP-1 RA-Supported Weight-Loss Program in the UK (n=8,294), 2024
• University of Oxford — systematic review of 37 studies (n=9,341) on weight regain after AOM discontinuation, January 2026
• Office for Health Improvement and Disparities (OHID) — Obesity profile short statistical commentary, May 2025
• NHS Digital — Health Survey for England 2024
• Eli Lilly UK price announcement (14 August 2025); The Pharmaceutical Journal coverage (15 August 2025); CNBC, Reuters
• Medicines and Healthcare products Regulatory Agency (MHRA) — Operation Dunlin press release, October 2025; ongoing MHRA enforcement updates
• UK Border Force FOI data
• House of Commons Library — Weight loss medicines in England research briefing
• Ipsos — Public attitudes towards weight loss injections, December 2025 (n=2,161)
• General Pharmaceutical Council (GPhC) — Updated guidance on online prescribing of weight management medicines, February 2025

Last updated: April 2026. We revise these figures quarterly as new IQVIA, NHS England and peer-reviewed UK studies are published.

This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional before starting any treatment.